Triple Therapy with Darbepoetin Alfa, Idebenone, and Riboflavin in Friedreich’s Ataxia: an Open-Label Trial
- 27 April 2013
- journal article
- clinical trial
- Published by Springer Nature in The Cerebellum
- Vol. 12 (5) , 713-720
Abstract
Minimal objective evidence exists regarding management of Friedreich’s ataxia (FRDA). Antioxidant and recombinant human erythropoietin therapies have been considered potential treatments to slow progression of FRDA in a small number of studies. The primary objective of the current study was to test the efficacy, safety, and tolerability of triple therapy—darbepoetin alfa, idebenone, and riboflavin—in FRDA in a clinical pilot study. Patients included in this study were nine females, 16 to 45 years of age (average 28 ± 8), diagnosed with FRDA with confirmed GAA repeat expansion mutations in the FXN gene and a GAA repeat ≥400 on the shorter allele. Patients had a baseline score between 8 and 28.5 (average 20.7 ± 8.3) on the scale for the assessment and rating of ataxia and 94.3 ± 27.2 g/m2 in left ventricular mass index (LVMI). Patients had been treated with triple therapy with 150 μg darbepoetin alfa every 2 or 3 weeks, 10–20 mg/kg/day idebenone, and 10–15 mg/kg/day riboflavin for 32 ± 19.4 months (range of 8–56 months). Triple therapy was tolerated. Although not statistically significant, improvement of ataxia was observed during the first six 4-month periods of the study. Furthermore, a small decrease in disease progression during the first 2 years of treatment was observed. Long-term statistically nonsignificant improvement of LVMI and stability of the echocardiographic parameters could be considered. Triple therapy may slow disease progression of FRDA.Keywords
This publication has 43 references indexed in Scilit:
- Erythropoietin in Friedreich ataxia: No effect on frataxin in a randomized controlled trialMovement Disorders, 2012
- Idebenone in Friedreich ataxia cardiomyopathy—results from a 6-month phase III study (IONIA)American Heart Journal, 2011
- Epoetin alfa increases frataxin production in Friedreich's ataxia without affecting hematocritMovement Disorders, 2010
- Flavin Adenine Dinucleotide Rescues the Phenotype of Frataxin DeficiencyPLOS ONE, 2010
- Diagnosis and treatment of Friedreich ataxia: a European perspectiveNature Reviews Neurology, 2009
- Neurological effects of recombinant human erythropoietin in Friedreich's ataxia: A clinical pilot trialMovement Disorders, 2008
- SARA—a new clinical scale for the assessment and rating of ataxiaNature Clinical Practice Neurology, 2007
- Mapping of the second Friedreich's ataxia (FRDAff2) locus to chromosome 9p23-p11: evidence for further locus heterogeneityneurogenetics, 2001
- Identification of three novel frameshift mutations in patients with Friedreich's ataxiaJournal of Medical Genetics, 2000
- Studies of human, mouse and yeast homologues indicate a mitochondrial function for frataxinNature Genetics, 1997